Dulaglutide Vs. Insulin Glargine for Type 2 Diabetes  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌   ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌
Can't see the images? View as webpage.
 
To ensure that you never miss an issue, please whitelist us.
DIABETES IN CONTROL | News and Information for Medical Professionals
DIC_23Years_Badge.png
     

Impact of Pharmacist-Led Education on Diabetes and Medication Adherence in Patients with T2D

THE IMPACT OF PHARMACIST LED EDUCATION ON DIABETES AND MEDICATION ADHERENCE IN PATIENTS WITH T2D
This study looked at pharmacist-led diabetes education and what effect it had on improving medication adherence. Factors such as A1C, systolic blood pressure, diet, and physical activity were also examined. Pharmacists were chosen for this study due to their high levels of patient interaction.
See the Impact

Dulaglutide Vs. Insulin Glargine for Type 2 Diabetes

Several studies have been conducted to compare dulaglutide, a GLP-1 RA, with insulin glargine. Therefore, Xu et al. conducted this meta-analysis to assess the efficacy and safety of two different doses of dulaglutide (1.5 mg and 0.75 mg) versus insulin glargine.
Get Results
DULAGLUTIDE VS INSULIN GLARGINE FOR T2D

ASSESSING RISKS OF INSULIN DETEMIR VS OTHER BASAL INSSULINS IN PREGNANT WOMEN WITH DIABETES
Assessing Risks of Insulin Detemir Vs. Other Basal Insulins in Pregnant Women with Diabetes

A study assessed the effects of detemir compared with other long-acting insulins on the risk of severe birth outcomes in women with pre-existing diabetes in a real-world setting. A randomized control trial investigated the use of detemir versus NPH insulin in combination with insulin aspart in pregnant women with type one diabetes only.
Learn More

     

  dic_icon_facebook  dic_icon_twitter   dic_icon_linkedIn

©2022 HIPER, LLC. All rights reserved.

This email was sent by eHealthcare Solutions on behalf of: Diabetes In Control

2093 Philadelphia Pike #8370
Claymont, DE 19703

DiabetesInControl.com | Contact Us |  Update Profile | Unsubscribe